Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › FDC

FDC

FDC Limited
Micro-capPharma ↗

What the six lenses say about FDC — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹342.1
2026-09-08
VWAP · 1Y anchor
₹410
-16.6% from VWAP
P/E · TTM
19.8×
TTM EPS ₹17.3
52-week range
13%
position low→high
RSI(14)
34
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How FDC’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
5.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD38›

The actual numbers

Price vs VWAP (1y)-16.6%
EMA trend stackDown · 21<50<200
Price vs 200-EMA-12.3%
Price vs 50-EMA-7.3%
RSI(14)34
RS vs Nifty 500 · 3M-14.7%
RS vs sector · 3M-20.7%
52-week range13%
Volume vs 30d avg0.26×
Volume vs 60d avg0.31×
ATR(14) · volatility11.3
Bollinger width · vol contraction0.074
FundamentalD542›

The actual numbers

Return on equity (ROE)11.3%
Operating margin17.5%
Net margin12.9%
Revenue growth · YoY+3.0%
EPS growth · YoY+5.4%
Debt / equity0.01×

Full 8-quarter history in the financials table below.

ValuationD865›

The actual numbers

P/E (TTM)19.8×
TTM EPS₹17.3
52-week range13%
CatalystD222›

The actual numbers

Earnings & momentum20
Capital actions17
Governance38

Every filing in the corporate-announcements panel below.

FlowD858›

The actual numbers

Promoter holding69.7%
Delivery · 30d avg56.4%
Up/down-day asymmetry3.1pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D3 + D8 ) ÷ 2 = 5.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Below threshold
13
Conviction score 13/100 · avg-decile strength 5.5/10
Conviction score13/100›
TechnicalD3›
FundamentalD5›
ValuationD8›
CatalystD2›
FlowD8›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.3pp
+2.7pp
-4.0pp
-13.1pp
-2.8pp
-22.6pp
Nifty 500
Broad-market baseline
+0.2pp
+2.7pp
-5.1pp
-14.7pp
-8.5pp
-27.8pp
Sector
Own-sector index
—
—
-7.9pp
-20.7pp
-21.7pp
-48.6pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

FDC daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
342.15-0.65

Relative strength

RS vs baseline · rebased to 100

FDC ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
61.71+0.14

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)638514464492648473465585
↳ change QoQ—-19.5%-9.7%+6.0%+31.7%-27.0%-1.7%+25.8%
EBITDA (₹cr)17510565541403452106
EBITDA margin27.4%20.4%14.1%11.0%21.6%7.2%11.2%18.1%
PAT (₹cr)1197237391212828103
↳ change QoQ—-39.5%-48.6%+5.3%+210.3%-76.9%+0.0%+267.9%
Net margin18.6%14.0%8.0%7.9%18.7%5.9%6.0%17.6%
EPS (₹)7.314.432.282.387.451.741.746.35
D/E————————
YoY growth · Mar '26Revenue +18.9% YoYPAT +164.1% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 27 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 5 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 28 May '26
    MEDIUMcapital
    Press Release (Revised)
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 27 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 27 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 27 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 18 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 May '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 24 Apr '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Apr '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 Mar '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 18 Mar '26
    MEDIUMgovernance
    Change in Director(s)
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds FDC

Mutual funds holding FDC (4)

FundWeightAUM ₹crGrade
ICICI Pru Smallcap Instl Gr0.73%9,533
ICICI Pru Smallcap Gr0.73%9,533
ICICI Pru Pharma Healthcare Diag Gr0.74%6,803
Tata India Pharma & Healthcare Reg Gr2.39%1,541

ETFs holding FDC (0)

No tracked ETF holds FDC ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma